2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
Playback speed
10 seconds
ASCO® 2024 Insights: "NEO-TIM Trial - Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-Risk Resectable Melanoma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Paolo A. Ascierto
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Paolo A. Ascierto
39 views
June 12, 2024
Chapters
NEO-TIM Trial & Drug Combination Overview
00:00
Study Design, Patient Enrollment & Baseline Characteristics
01:40
Clinical Trial Results & Safety Evaluation
04:04
Comments 0
Login to view comments.
Click here to Login